Online inquiry

IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5556MR)

This product GTTS-WQ5556MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5556MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4504MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ1080MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ15923MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ9940MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ1803MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ5494MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ2159MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ13890MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2176
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW